TIUMBIO CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 7,430 KRW | -4.38% |
|
-0.27% | -23.95% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
| Sales 2022 | 9.12B 6.66M | Sales 2023 | 4.9B 3.58M | Capitalization | 241B 176M |
|---|---|---|---|---|---|
| Net income 2022 | -29.85B -21.82M | Net income 2023 | -17.91B -13.09M | EV / Sales 2022 | 31.9 x |
| Net cash position 2022 | 11.89B 8.69M | Net cash position 2023 | 678M 496K | EV / Sales 2023 | 49 x |
| P/E ratio 2022 |
-10.1
x | P/E ratio 2023 |
-13.3
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 57.93% |
More Fundamentals
* Assessed data
More news
| 1 day | -4.38% | ||
| 1 week | -0.27% | ||
| Current month | +0.81% | ||
| 1 month | +1.23% | ||
| 3 months | -6.19% | ||
| 6 months | +9.59% | ||
| Current year | -23.95% |
1 week
7 300.00
8 400.00
1 month
6 400.008 400.00
Current year
6 400.0010 240.00
1 year
6 290.0011 370.00
3 years
6 290.0027 500.00
5 years
5 800.0029 650.00
10 years
5 800.0029 650.00
| Managers | Title | Age | Since |
|---|---|---|---|
Hoon-Taek Kim
CEO | Chief Executive Officer | 58 | - |
Hyun-Sil Go
DFI | Director of Finance/CFO | 45 | - |
In-Young Song
BRD | Director/Board Member | 51 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Mahn-Soon Hwang
BRD | Director/Board Member | 54 | - |
Hoon-Taek Kim
CEO | Chief Executive Officer | 58 | - |
In-Young Song
BRD | Director/Board Member | 51 | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-10 | 7,430 | -4.38% | 883,196 |
| 24-05-09 | 7,770 | +1.70% | 148,318 |
| 24-05-08 | 7,640 | +4.66% | 316,519 |
| 24-05-07 | 7,300 | -5.56% | 246,761 |
End-of-day quote Korea S.E., May 09, 2024
More quotes
TiumBio Co., Ltd. is a Korea-based company principally engaged in the research and development of biopharmaceuticals. The Company researches and develops small molecule drugs including endometriosis treatments, uterine fibroids treatments, cancer immunotherapy drugs; and new biopharmaceuticals including hemophilia treatments, and others.
Calendar
2024-05-12
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -23.95% | 140M | |
| +3.91% | 109B | |
| +10.87% | 105B | |
| 0.00% | 22.25B | |
| -13.14% | 22.09B | |
| -7.82% | 18.68B | |
| -38.36% | 17.58B | |
| -10.66% | 16.85B | |
| +3.75% | 13.76B | |
| +36.70% | 12.46B |
- Stock Market
- Equities
- A321550 Stock